ARTICLE | Emerging Company Profile

Mining for functionality

HiFiBiO's single cell-based platform discovers diverse, functional antibodies

May 19, 2016 7:00 AM UTC

Conventional antibody discovery platforms generate a small number of candidates that block a target, and even fewer that can alter the function of target cells. HiFiBiO S.A.S. has a platform that improves the odds of finding a viable therapeutic by rapidly producing large, genetically diverse sets of functional antibodies.

Standard platforms like phage display and hybridoma-based systems select antibodies based primarily on their ability to bind the target antigen. "So if you're looking for antibodies that make a functional change in a target cell, these platforms alone aren't sufficient," Chief Commercial Officer Colin Brenan told BioCentury...